Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer

Few companies understand PD-1 biology better than Merck. Keytruda has defined the modern immuno-oncology era and remains the foundation of Merck's oncology business.

That is exactly why Merck's attitude toward PD-1/VEGF bispecific antibodies matters. For a long time, the company's tone was cautious. The core question was whether the class could turn progression-free-survival improvement into overall-survival benefit. If not, Keytruda's position would remain largely protected.

After ASCO 2026, the tone looks different.

Merck has given MK-2010, formerly LM-299 from LaNova, a clearer place in its oncology narrative. The asset blocks both PD-1 and VEGF, combining checkpoint inhibition and anti-angiogenesis in one molecule. Early human data remain limited, but Merck described preliminary activity in non-small cell lung cancer and continued exploration as both monotherapy and in combinations.

The class became harder to dismiss after HARMONi-6. Ivonescimab plus chemotherapy showed an overall-survival advantage versus tislelizumab plus chemotherapy in first-line advanced squamous NSCLC. For a PD-1/VEGF bispecific, the key point was not only PFS. It was the possibility that dual-mechanism biology could produce survival benefit.

Merck still has reasonable questions. Can China data be extrapolated globally? Will elderly and comorbid patients tolerate the mechanism? Are safety risks such as hypertension, bleeding, proteinuria, thrombosis, and immune-related adverse events manageable at scale? Which tumor types and combinations are the right sweet spots?

Those questions matter. But the strategic shift is that Merck appears to be asking where and how to use the mechanism, not whether the mechanism deserves attention at all.

The other layer is Merck's broader post-Keytruda package. The company is not relying only on MK-2010. It also has sacituzumab tirumotecan, a TROP2 ADC, and other oncology assets that could be paired with immunotherapy backbones. The future may not be one successor to Keytruda, but a set of combinations: PD-1/VEGF bispecifics, ADCs, Keytruda, and other targeted or immune-modulating agents.

For investors, Merck's dilemma is simple. Keytruda is too successful to abandon, but the company cannot risk missing the next immuno-oncology backbone. MK-2010 is not yet the answer, but it has become an option Merck can no longer ignore.

That is the real meaning of Merck's shift. The Keytruda throne is still standing, but the shape of the next oncology throne is becoming visible.

This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.

Original Article

Read This Next

Continue with the most relevant Drugnews analysis on the same theme.

OncologyPD-1 VEGFoncology

Jun 30, 2026Business AnalysisFree Article

GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy

GSK's $10.6 billion all-cash acquisition of Nuvalent is more than a late-stage lung-cancer pipeline deal. It is a strategic attempt to rebuild oncology, buy time before major revenue pressure, and regain a seat at the precision-oncology table.

GSKNuvalentOncologyLung cancerROS1

Jun 15, 2026Medical ConferenceFree Article

ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle

ASCO 2026 showed that oncology is moving from single-mechanism breakthroughs toward platform combinations across RAS targeting, ADCs, PD-1/VEGF bispecifics, and in vivo CAR-T.

ASCOOncologyRASADCPD-1 VEGF

Jul 02, 2026Business AnalysisFree Article

Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find

PARP inhibitors turned synthetic lethality into a commercial reality. Two decades later, the industry is still asking why the next PARP-like blockbuster has been so difficult to reproduce.

synthetic lethalityPARPPRMT5MTAPRAS